Paraneoplastic cerebellar degeneration

Introduction. Paraneoplastic cerebellar degeneration (PCD) is an immune-mediated and rapidly progressive cerebellar syndrome that develops as a result of a cross-immune response to the common antigens for the tumor and cerebellar cells. Timely diagnosis and treatment of PCD improves the functional status and survival of these patients.
Objective. To analyze the clinical, laboratory and neuroimaging characteristics of PCD case series in comparison with literature data.
Material and methods. 16 patients with PCD (13 women, 3 men) were examined. An assessment of the clinical presentation, brain MRI study, blood and cerebrospinal fl uid laboratory tests were carried out, the data of cancer search and patients follow-up were analyzed.
Results. The median age of PCD patients was 55 years, the duration of the disease was 8.5 months (range 4 to 16 months). In 12 patients, PCD was the fi rst manifestation of cancer. The clinical prentation was presented by rapidly progressive cerebellar ataxia, often in combination with oculomotor disturbances, pyramidal and bulbar syndrome, hand tremor and dystonia. An associated cancers were detected in 13 patients (81%). Antineuronal antibodies were found in 14 patients (88%): anti-Yo-1, antibodies to amphiphysin, anti-Hu, anti-CV2 and anti-GAD. Mild atrophic changes of the cerebellum were found in 6 patients, and in 2 cases cerebellar hemiatrophy was observed.
Conclusion. PCD is a rare disabling but potentially curable disease. The basis of diagnosis is the analysis of the clinical presentation and neuroimaging data, the detection of antineuronal antibodies and in fl ammatory changes in the cerebrospinal fl uid, as well as a thorough cancer search.

1. Vogrig A., Gigli G.L., Segatti S., Corazza E., Marini A., Bernardini A. et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. Journal of Neurology. 2019;267(1):26–35. PMID: 31552550 https://doi.org/10.1007/s00415-019-09544-1

2. Graus F., Vogrig A., Muñiz-Castrillo S., Antoine J.G., Desestret V., Dubey D. et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroin fl amm. 2021;8(4):e1014. PMID: 34006622 https://doi.org/10.1212/NXI.0000000000001014

3. Loehrer P.A., Zieger L., Simon O.J. Update on Paraneoplastic Cerebellar Degeneration. Brain Sci. 2021;11(11):1414. PMID: 34827413 https://doi.org/10.3390/brainsci11111414

4. Лапин С.В., Шулешова Н.В., Скоромец А.А., Тотолян А.А. Антитела при паранеопластических неврологических синдромах: подострая дегенерация мозжечка с антителами против клеток Пуркинье (РСА-1). Медицинская иммунология. 2000;2(4):439–446. [Lapin S.V., Shuleshova N.V., Skoromets A.A., Totolian A.A. Subacute paraneoplastic cerebellar degeneration in patient with Purkinje cell antibodies (PCA-1). Medical Immunology (Meditsinskaya Immunologiya). 2000;2(4):439–446. (In Russ.)].

5. Шнайдер Н.А., Ежикова В.В., Дыхно Ю.А., Дмитренко Д., Панина Ю. Проблемы диагностики паранеопластической мозжечковой дегенерации. Неврология, нейропсихиатрия, психосоматика. 2014;(1):35–43. [Shnaider N., Ezhikova V., Dykhno Yu., Dmitrenko D., Panina Yu. Diagnosis problems of paraneoplastic cerebellar degeneration. Neurology, Neuropsychiatry, Psychosomatics (Nevrologia, nejropsihiatria, psihosomatika). 2014;6(1):35–43. (In Russ.)]. https://doi.org/10.14412/2074-2711-2014-1-35-43

6. Королёва Е.С., Алифирова В.М., Рязанцева А.А., Кощавцева Ю.И. Паранеопластическая мозжечковая дегенерация у пациента с антителами anti-Yo и аденокарциномой простаты. Бюллетень сибирской медицины. 2017;16(3):218–223. [Koroleva E.S., Alifi rova V.M., Ryazantseva A.A., Koshavtseva Yu.I. Paraneoplastic cerebellar degeneration in a patient with anti-Yo antibodies and prostate adenocarcinoma. Bulletin of Siberian Medicine (Bûlletenʹ sibirskoj mediciny). 2017;16(3):218–223. (In Russ.)]. https://doi.org/10.20538/1682-0363-2017-3-218-223

7. Лебедев В.М., Прахова Л.Н., Новоселова О.М., Амелин А.В., Савинцева Ж.И. Паранеопластическая мозжечковая дегенерация. Неврологический журнал. 2019;24(1):35–41. [Lebedev V.M., Prakhova L.N., Novoselova O.M., Amelin A.V., Savintseva Zh.I. Paraneoplastic cerebellar degeneration. The Neurological Journal (Nevrologicheskiy Zhurnal). 2019;24(1):35–41. (In Russ.)]. https://doi.org/10.18821/1560-9545-2019-24-1-35-41

8. Nuzhnyi E., Fedotova E., Kovrigina A., Glinkina S., Moskalenko A., Illarioshkin S. Immune-mediated ataxia with cerebellar hemiatrophy and dystonia associated with Castleman disease. Clinical neurology and neurosurgery. 2021;200:106407. https://doi.org/10.1016/j.clineuro.2020.106407

9. Mitoma H., Manto M., Hampe C.S. Immune-mediated cerebellar ataxias: Practical guidelines and therapeutic challenges. Current Neuropharmacology. 2019;17(1):33–58. PMID: 30221603 https://doi.org/10.2174/1570159x16666180917105033

10. Grativvol R.S., Cavalcante W.C.P., Castro L.H.M., Nitrini R., Simabukuro M.M. Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes. Curr. Oncol. Rep. 2018;20(11):92. PMID: 30415318 https://doi.org/10.1007/s11912-018-0721-y

11. Darnell R.B., Posner J.B. Paraneoplastic Syndromes Involving the Nervous System. N Engl J Med. 2003:349(16):1543–54. PMID: 14561798 https://doi.org/10.1056/NEJMra023009

12. Peterson K., Rosenblum M.K., Kotanides H., Posner J.B. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 antiYo antibody-positive patients. Neurology. 1992;(10):1931–1937. PMID: 1407575 https://doi.org/10.1212/wnl.42.10.1931

13. Rosenfeld M.R., Dalmau J. Paraneoplastic Neurologic Syndromes. Neurol Clin. 2018;36(3):675–685. PMID: 30072076 https://doi.org/10.1016/j.ncl.2018.04.015

14. Ducray F., Demarquay G., Graus F., Decullier E., Antoine J.C., Giometto B. et al. Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience. European journal of neurology. 2014;21(5):731–735. PMID: 24471811 https://doi.org/10.1111/ene.12368

15. Greenlee J.E. Treatment of paraneoplastic cerebellar degeneration. Current treatment options in neurology. 2013;15(2):185–200. PMID: 23315179 https://doi.org/10.1007/s11940-012-0215-4

16. Narayan R.N., McKeon A., Fife T.D. Autoimmune Vestibulocerebellar Syndromes. Seminars in neurology. 2020;40(1):97–115. PMID: 31958862 https://doi.org/10.1055/s-0039-3402061

17. Venkatraman A., Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies — a review. Annals of clinical and translational neurology. 2016;3(8):655–663. PMID: 27606347 https://doi.org/10.1002/acn3.328

18. Muniz-Castrillo S., Honnorat J. Paraneoplastic Neurological Syndromes. In: Mitoma H., Manto M. (eds) Neuroimmune Diseases. Contemporary Clinical Neuroscience. Springer. 2019. https://doi.org/10.1007/978-3-030-19515-1_14

19. Saloustros E., Zaganas I., Mavridis M., Vamvakas L., Plaitakis A., Georgoulias V., Mavroudis D. Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. Journal of neuro-oncology. 2010;97(2):291–294. PMID: 19798470 https://doi.org/10.1007/s11060-009-0022-2

20. Afzal S., Recio M., Shamim S. Paraneoplastic cerebellar ataxia and the paraneoplastic syndromes. Proc (Bayl Univ Med Cent). 2015;28(2):217–220. PMID: 25829659 https://doi.org/10.1080/08998280.2015.11929234

21. Нужный Е.П., Краснов М.Ю., Ахмадуллина Д.Р., Абрамова А.А., Федотова Е.Ю., Иллариошкин С.Н. Атаксия, ассоциированная с антителами к глутаматдекарбоксилазе. Неврология, нейропсихиатрия, психосоматика. 2020;12(5):66–70. [Nuzhnyi E.P., Krasnov M.Yu., Akhmadullina D.R., Abramova A.A., Fedotova E.Yu., Illarioshkin S.N. Ataxia associated with anti-glutamic acid decarboxylase antibodies. Neurology, Neuropsychiatry, Psychosomatics (Nevrologiya, neiropsikhiatriya, psikhosomatika). 2020;12(5):66–70. (In Russ.)]. https://doi.org/10.14412/2074-2711-2020-5-66-70

22. Qian S.X., Li J.Y., Hong M., Xu W., Qiu, H. X. Nonhematological autoimmunity (glomerulosclerosis, paraneoplastic pemphigus and paraneoplastic neurological syndrome) in a patient with chronic lymphocytic leukemia: Diagnosis, prognosis and management. Leukemia research. 2009;33(3):500–505. PMID: 18805582 https://doi.org/10.1016/j.leukres.2008.07.031

23. Nogai H., Israel-Willner H., Zschenderlein R., Pezzutto A. Improvement of paraneoplastic limbic encephalitis after systemic treatment with rituximab in a patient with B-cell chronic lymphocytic leukemia. Case reports in hematology. 2013;2013:958704. PMID: 23984126 https://doi.org/10.1155/2013/958704

24. Derksen A., Stettner M., Stöcker W., Seitz R.J. Antiglycine receptor-related stiff limb syndrome in a patient with chronic lymphocytic leukaemia. BMJ case reports. 2013;2013:bcr2013008667. PMID: 23696138 https://doi.org/10.1136/bcr-2013-008667

25. Lee S., Le S. A New Association Between Castleman Disease and Immune-Mediated Cerebellitis. JAMA neurology. 2015;72(6):722–723. PMID: 26053442 https://doi.org/10.1001/jamaneurol.2015.0091

26. Hamaji M., Neal J.W., Burt B.M. Unicentric, multifocal Castleman disease of the mediastinum associated with cerebellitis. The Annals of thoracic surgery. 2015;99(1):e7–e9. PMID: 25555986 https://doi.org/10.1016/j.athoracsur.2014.10.028

27. Ayas Z.O., Uncu G. A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma. Current oncology (Toronto, Ont.). 2021;28(1):560–564. PMID: 33477892 https://doi.org/10.3390/curroncol28010055

28. Hirunagi T., Sato K., Fujino M., Tanaka K., Goto Y., Mano K. [Subacute cerebellar ataxia with amphiphysin antibody developing in a patient with follicular thyroid adenoma: a case report] Rinsho shinkeigaku (Clinical neurology). 2016;56(11):769–772. PMID: 27773907 https://doi.org/10.5692/clinicalneurol.cn-000939

29. Escudero D., Guasp M., Arino H., Gaig C., Martínez-Hernandez E., Dalmau J., Graus F. Antibody-associated CNS syndromes without signs of infl ammation in the elderly. Neurology. 2017;89(14):1471–1475. PMID: 28878050 https://doi.org/10.1212/WNL.0000000000004541

30. Casciato S., Mascia A., Quarato P.P., D’Aniello A., Scoppetta C., Di Gennaro G. Subacute cerebellar ataxia as presenting symptom of systemic lupus erythematosus. Eur Rev Med Pharmacol Sci. 2018;22(21):7401–7403. PMID: 30468487 https://doi.org/10.26355/eurrev_201811_16279

31. Mitoma H., Manto M., Hampe C.S. Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges. Current neuropharmacology. 2019;17(1):33–58. PMID: 30221603 https://doi.org/10.2174/1570159X16666180917105033

32. Paul N.L., Kleinig T.J. Therapy of paraneoplastic disorders of the CNS. Expert Rev Neurother. 2015;15(2):187–193. PMID: 25614953 https://doi.org/10.1586/14737175.2015.1000310